



PB 135 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024

I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 28 November 2024

Eden Simon
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 December 2024	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 11) 2024*.
- (2) This instrument may also be cited as PB 135 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 December 2024.	1 December 2024
2. Schedule 1	1 December 2024.	1 December 2024

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 December 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Acarbose	After: Tablet 50 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
Aciclovir	insert: Tablet 200 mg	Oral	Aciclovir APOTEX	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together
Aciclovir	Tablet 200 mg	Oral	ARX-ACICLOVIR	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together
Aciclovir	Tablet 800 mg	Oral	Aciclovir APOTEX	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together
Aciclovir	Tablet 800 mg	Oral	ARX-ACICLOVIR	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together

2 Schedule 1 (table)

Allopurinol	After: Tablet 100 mg	Oral	Allosig	3 months stock by reference to usual demand
Allopurinol	insert: Tablet 100 mg	Oral	APO-ALLOPURINOL	4 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together

3 Schedule 1 (table)

	After:				
Allopurinol	Tablet 100 mg	Oral	Zyloprim	3 months stock by reference to usual demand	
	insert:				
Allopurinol	Tablet 300 mg	Oral	APO-ALLOPURINOL	6 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together	

4 Schedule 1 (table)

	After:			
Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	ENTRIP	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand
	insert:			
Amlodipine	Tablet 5 mg (as besilate)	Oral	APX-AMLODIPINE	6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together

5 Schedule 1 (table)

	After:			
Atomoxetine	Capsule 80 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
	insert:			
Azacitidine	Powder for injection 100 mg	Injection	Azacitidine-Teva	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand

6 Schedule 1 (table)

After:

Bisoprolol	Tablet containing bisoprolol fumarate 5 mg	Oral	Cipla Bisoprolol	between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand
insert:				
Bivalirudin	Powder for I.V. injection 250 mg (as trifluoroacetate)	Injection	Bivalirudin APOTEX	4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together
Bivalirudin	Powder for I.V. injection 250 mg (as trifluoroacetate)	Injection	BIVALIRUDIN ARX	4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together

7 Schedule 1 (table)

After:

Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the Eye	Optive	between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand
insert:				
Cefazolin	Powder for injection 1 g (as sodium)	Injection	Cefazolin-AFT	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand

8 Schedule 1 (table)

Omit:

Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime Kabi	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand
Cefepime	Powder for injection 2 g (as hydrochloride)	Injection	Cefepime Kabi	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand

9 Schedule 1 (table)

After:

Ciclosporin	Capsule 100 mg	Oral	APO-Ciclosporin	2.5 months stock by reference to usual demand
	insert:			
Ciclosporin	Capsule 100 mg	Oral	Cyclosporin Sandoz	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand

10 Schedule 1 (table)

	After:			
Ciclosporin	Capsule 25 mg	Oral	APO-Ciclosporin	3 months stock by reference to usual demand
	insert:			
Ciclosporin	Capsule 25 mg	Oral	Cyclosporin Sandoz	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand

11 Schedule 1 (table)

	After:			
Ciclosporin	Capsule 50 mg	Oral	APO-Ciclosporin	3 months stock by reference to usual demand
	insert:			
Ciclosporin	Capsule 50 mg	Oral	Cyclosporin Sandoz	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand

12 Schedule 1 (table)

	After:			
Clonazepam	Oral liquid 2.5 mg per mL, 10 mL	Oral	Rivotril	6 months stock by reference to usual PBS demand
	insert:			
Clopidogrel with aspirin	Tablet 75 mg (as hydrogen sulfate)-100 mg	Oral	Clopidogrel Winthrop plus aspirin	between 1 December 2024 and 31 March 2025—0 months stock by reference to usual demand

13 Schedule 1 (table)

	After:			
Entecavir	Tablet 0.5 mg (as monohydrate)	Oral	Entecavir Viartis	after 30 September 2024—4 months stock by reference to

				usual demand of both Entecavir Viatris and Entecavir Mylan added together
	insert:			
Entecavir	Tablet 1 mg (as monohydrate)	Oral	Entecavir Viatris	after 28 February 2025— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together

14 Schedule 1 (table)

	Omit:			
Epoprostenol	Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL	Injection	Flolan	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand
Epoprostenol	Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL	Injection	Flolan	between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand

15 Schedule 1 (table)

	After:			
Fentanyl	Transdermal patch 8.4 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
	insert:			
Fluconazole	Capsule 200 mg	Oral	APO-Fluconazole	4 months stock by reference to usual demand of both Fluconazole APOTEX and APO-Fluconazole added together

16 Schedule 1 (table)

	Omit:			
Furosemide	Oral solution 10 mg per ml, 30 ml	Oral	Lasix	(a) between 1 November 2024 and 31 March 2024—4 months stock by reference to usual PBS demand (b) after 31 March 2024—6 months

					stock by reference to usual PBS demand
	substitute:				
Furosemide	Oral solution 10 mg per ml, 30 ml	Oral	Lasix	(a) between 1 November 2024 and 31 March 2025—4 months stock by reference to usual PBS demand (b) after 31 March 2025—6 months stock by reference to usual PBS demand	

17 Schedule 1 (table)

	After:				
Gabapentin	Capsule 400 mg	Oral	GAPENTIN	3 months stock by reference to usual demand	
	insert:				
Gabapentin	Tablet 600 mg	Oral	APX-GABAPENTIN	4 months stock by reference to usual demand of both Gabapentin APOTEX and APX-GABAPENTIN added together	

18 Schedule 1 (table)

	After:				
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand	
	insert:				
Glimepiride	Tablet 1 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together	
Glimepiride	Tablet 1 mg	Oral	Glimepiride APOTEX	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together	
Glimepiride	Tablet 2 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual	

				demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 2 mg	Oral	Glimepiride APOTEX	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 3 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 3 mg	Oral	Glimepiride APOTEX	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 4 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 4 mg	Oral	Glimepiride APOTEX	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together

19 Schedule 1 (table)

Omit:

Imatinib	Capsule 100 mg (as mesilate)	Oral	Imatinib-APOTEX	3 months stock by reference to usual demand
Imatinib	Capsule 400 mg (as mesilate)	Oral	Imatinib-APOTEX	3 months stock by reference to usual demand

20 Schedule 1 (table)

After:

Hypromellose with carbomer 980	Ocular lubricating gel 3 mg-2 mg per g, 10 g	Application to the Eye	HPMC PAA	between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand
Imatinib	insert: Capsule 100 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together
Imatinib	Capsule 100 mg (as mesilate)	Oral	Imatinib-APOTEX	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together
Imatinib	Capsule 400 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together
Imatinib	Capsule 400 mg (as mesilate)	Oral	Imatinib-APOTEX	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together

21 Schedule 1 (table)

After:

Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	Oral	AVSARTAN HCT 150/12.5	4 months stock by reference to usual demand
-------------------------------------	-----------------------	------	-----------------------	---

insert:

Iron polymaltose complex	Injection 100 mg (iron) in 2 mL	Injection	Ferrosig	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
--------------------------	---------------------------------	-----------	----------	---

22 Schedule 1 (table)

After:

Latanoprost with timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as	Application to the Eye	APO-Latanoprost/Ti molol 0.05/5	2.5 months stock by reference to usual demand
--------------------------	---	------------------------	---------------------------------	---

	maleate) per mL, 2.5 mL				
	insert:				
Leflunomide	Tablet 10 mg	Oral	APO-LEFLUNOMIDE	4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together	
Leflunomide	Tablet 20 mg	Oral	APO-LEFLUNOMIDE	4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together	
Lercanidipine	Tablet containing lercanidipine hydrochloride 10 mg	Oral	ARX-LERCANIDIPINE	6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together	
Lercanidipine	Tablet containing lercanidipine hydrochloride 20 mg	Oral	ARX-LERCANIDIPINE	6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together	
Letrozole	Tablet 2.5 mg	Oral	ARX-LETROZOLE	4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together	
Letrozole	Tablet 2.5 mg	Oral	Letrozole APOTEX	4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together	

23 Schedule 1 (table)

	After:			
Milk protein and fat formula with vitamins and minerals -- carbohydrate free	Oral powder 225 g (Carbohydrate Free Mixture)	Oral	Carbohydrate Free Mixture	6 months stock by reference to usual PBS demand
	insert:			

Mirtazapine	Tablet 45 mg	Oral	NOUMED MIRTAZAPINE	between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand
-------------	--------------	------	-----------------------	---

24 Schedule 1 (table)

After:

Modafinil	Tablet 100 mg	Oral	Modafin	3 months stock by reference to usual demand
-----------	---------------	------	---------	---

insert:

Modafinil	Tablet 100 mg	Oral	Modafinil Viatris	after 28 February 2025— 4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together
-----------	---------------	------	-------------------	--

Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral	APX-Montelukast	4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together
-------------	------------------------------------	------	-----------------	---

Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral	APX-Montelukast	4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together
-------------	------------------------------------	------	-----------------	---

Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	ARX-MYCOPHENOLAT E	4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLAT E added together
-------------------	--	------	--------------------	--

Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	Mycophenolate APOTEX	4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLAT E added together
-------------------	--	------	----------------------	--

25 Schedule 1 (table)

After:

Nortriptyline	Tablet 25 mg (as hydrochloride)	Oral	NortriTABS 25 mg	between 1 October 2024 and 31 December 2024—0 months stock by
---------------	---------------------------------	------	------------------	---

				reference to usual demand
	insert:			
Olanzapine	Tablet 10 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together

26 Schedule 1 (table)

	After:			
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together.
	insert:			
Olanzapine	Tablet 2.5 mg	Oral	APO-OLANZAPINE	6 months stock by reference to usual demand of both Olanzapine APOTEX and APO-

OLANZAPINE
added together

27 Schedule 1 (table)

Olanzapine	After: Tablet 20 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral; (b) between 1 October 2024 and 31 March 2025— 4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together
------------	---	------	------------	---

Olanzapine	insert: Tablet 5 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO- OLANZAPINE added together
------------	------------------------	------	----------------	--

28 Schedule 1 (table)

Olanzapine	After: Tablet 5 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months
------------	--	------	------------	---

				stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;
				(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together
	insert:			
Olanzapine	Tablet 7.5 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together

29 Schedule 1 (table)

	After:			
Olmesartan	Tablet containing olmesartan medoxomil 40 mg	Oral	OLMERTAN	(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand

insert:				
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	Oral	APO-OLMESARTAN/A MLODIPINE 20/5	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO-OLMESARTAN/A MLODIPINE 20/5 mg added together
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	Oral	APO-OLMESARTAN/A MLODIPINE 40/10	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/10 APOTEX and APO-OLMESARTAN/A MLODIPINE 40/10 added together
Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	Oral	APO-OLMESARTAN/A MLODIPINE 40/5	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO-OLMESARTAN/A MLODIPINE 40/5 mg added together

30 Schedule 1 (table)

After:				
Pantoprazole	Sachet containing granules 40 mg (as sodium sesquihydrate)	Oral	Somac	4 months stock by reference to usual PBS demand
insert:				
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together

31 Schedule 1 (table)

After:				
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APO-Pantoprazole	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

	insert:			
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together

32 Schedule 1 (table)

	After:			
Permethrin	Cream 50 mg per g, 30 g	Application	Lyclear	6 months stock by reference to usual PBS demand
	insert:			
Phenoxymethylpenicillin	Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL	Oral	Phenoxymethylpenicillin-AFT	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand

33 Schedule 1 (table)

	After:			
Pimecrolimus	Cream 10 mg per g, 15 g	Application	Elidel	6 months stock by reference to usual PBS demand
	insert:			
Pioglitazone	Tablet 15 mg (as hydrochloride)	Oral	APOTEX-Pioglitazone	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 15 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	APOTEX-Pioglitazone	4 months stock by reference to usual demand of both APOTEX-

				Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	APOTEX-Pioglitazone	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together

34 Schedule 1 (table)

After:

Protein hydrolysate formula with medium chain triglycerides	Oral powder 450 g (Aptamil Gold+ Pepti-Junior)	Oral	Aptamil Gold+ Pepti-Junior	6 months stock by reference to usual PBS demand
---	--	------	----------------------------	---

insert:

Quetiapine	Tablet 100 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together
Quetiapine	Tablet 200 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together
Quetiapine	Tablet 25 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-

				QUETIAPINE added together
Quetiapine	Tablet 300 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together

35 Schedule 1 (table)

	After:			
Risperidone	Tablet 3 mg	Oral	Rispa	3 months stock by reference to usual demand
	insert:			
Rizatriptan	Tablet (orally disintegrating) 10 mg (as benzoate)	Oral	APO-RIZATRIPTAN ODT	4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO-RIZATRIPTAN ODT added together
Rosuvastatin	Tablet 10 mg (as calcium)	Oral	APO-Rosuvastatin	6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-Rosuvastatin added together
Rosuvastatin	Tablet 20 mg (as calcium)	Oral	APO-ROSUVASTATIN	4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin	Tablet 40 mg (as calcium)	Oral	APO-ROSUVASTATIN	4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	APO-ROSUVASTATIN	6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together

36 Schedule 1 (table)

Omit:

Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 ml single dose units, 30	Inhalation	Salbutamol Cipla	between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand.
Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30	Inhalation	Salbutamol Cipla	between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand.

37 Schedule 1 (table)

After:				
Sertraline	Tablet 50 mg (as hydrochloride)	Oral	NOUMED SERTRALINE	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
insert:				
Sevelamer	Tablet containing sevelamer carbonate 800 mg	Oral	ARX-SEVELAMER	4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together
Sevelamer	Tablet containing sevelamer carbonate 800 mg	Oral	Sevelamer Apotex	4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together

38 Schedule 1 (table)

After:				
Tacrolimus	Capsule 5 mg	Oral	Tacrograf	3 months stock by reference to usual demand
insert:				
Telmisartan	Tablet 40 mg	Oral	NOUMED TELMISARTAN	between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand

39 Schedule 1 (table)

After:				
Temazepam	Tablet 10 mg	Oral	APO-Temazepam	2.5 months stock by reference to usual demand
insert:				

Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Tenofovir APOTEX	4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together
Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Tenofovir ARX	4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together

40 Schedule 1 (table)

Omit:

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	Tenofovir/Emtricitabine 300/200 APOTEX	3 months stock by reference to usual demand
------------------------------	--	------	--	---

41 Schedule 1 (table)

After:

Tenofovir	Tablet containing tenofovir disoproxil maleate 300 mg	Oral	Tenofovir Disoproxil Viartis	after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viartis and Tenofovir Disoproxil Mylan added together
-----------	---	------	------------------------------	---

insert:

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	Tenofovir/Emtricitabine 300/200 APOTEX	3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together
------------------------------	--	------	--	---

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	TENOFOVIR/EMTRICITABINE 300/200 ARX	3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together
------------------------------	--	------	-------------------------------------	---

42 Schedule 1 (table)

	After:				
Valproic acid	Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Syrup		6 months stock by reference to usual PBS demand
	insert:				
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	APO-Sodium Valproate		between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Epilim EC		between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Sodium Valproate Sandoz		between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Valprease 200		between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Valpro EC 200		between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Valproate Winthrop EC 200		between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	APO-Sodium Valproate		between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Epilim EC		between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Sodium Valproate Sandoz		between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand

Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Valprease 500	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Valpro EC 500	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Valproate Winthrop EC 500	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand

43 Schedule 1 (table)

Omit:

Vancomycin	Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together
------------	--	-----------	--------------------	---

substitute:

Vancomycin	Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together
------------	--	-----------	--------------------	---

44 Schedule 1 (table)

Omit:

Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together
------------	---	-----------	--------------------	---

substitute:

Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together
------------	---	-----------	--------------------	---